8-K: 2seventy bio Completes Sale of Oncology and Autoimmune Pipeline to Regeneron, Shifts Focus to Abecma

2seventy bio has finalized the sale of its oncology and autoimmune programs to Regeneron for $5 million upfront, shifting its focus to the commercialization of Abecma.

Summary

• 2seventy bio completed the sale of its oncology and autoimmune research and development programs, clinical manufacturing capabilities, and related platform technologies to Regeneron for an upfront payment of $5 million.
• Regeneron also assumed certain liabilities and subleased 2seventy bio's facilities in Cambridge, Massachusetts and Seattle, Washington.
• 2seventy bio may receive a $10 million milestone payment upon regulatory approval of the first product from the transferred assets in certain countries, as well as royalties on net sales if commercialized.
• The existing collaboration agreement between 2seventy bio and Regeneron regarding certain programs was terminated as part of the deal.
• Following the sale, 2seventy bio will now focus exclusively on the development and commercialization of Abecma, its CAR T-cell therapy for multiple myeloma, in collaboration with Bristol Myers Squibb.
• The company has reduced its workforce to approximately 65 full-time employees, primarily in quality and supporting functions.
• The cost savings from the reduced headcount and the sale of the pipeline assets are expected to extend 2seventy bio's cash runway beyond 2027.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While the company has divested a significant portion of its business, it has secured funding and extended its cash runway, allowing it to focus on its lead product. However, the reliance on a single product and the potential risks associated with it temper the overall positive outlook.

Positives

• The sale of the oncology and autoimmune pipeline provides 2seventy bio with immediate cash of $5 million.
• The potential for a $10 million milestone payment and future royalties offers additional financial upside.
• Focusing solely on Abecma allows 2seventy bio to concentrate its resources on a key product.
• The reduction in workforce and associated cost savings extends the company's cash runway beyond 2027.
• The company retains the ability to support quality control of lentiviral vector (LVV) for Abecma.

Negatives

• The company has divested its entire oncology and autoimmune research and development pipeline.
• The company has reduced its workforce significantly.
• The $10 million milestone payment is not guaranteed and is contingent on regulatory approval.
• The company is now reliant on the success of a single product, Abecma.

Risks

• The success of 2seventy bio is now heavily dependent on the commercial success of Abecma.
• There is a risk that Abecma may not achieve the anticipated commercial success or receive further regulatory approvals.
• The strategic realignment may not achieve the anticipated cost savings or may cause disruptions in the business.
• The company may face challenges in managing its operating expenses and cash use.
• The company is reliant on its collaboration with Bristol Myers Squibb for the success of Abecma.

Future Outlook

2seventy bio will focus exclusively on the commercialization and development of Abecma, with the goal of bringing it to more patients in earlier lines of treatment. The company expects to continue to support quality control of lentiviral vector (LVV) for Abecma and has extended its cash runway beyond 2027.

Management Comments

• Chip Baird, CEO, stated that the company is pleased to have successfully transitioned its innovative cell therapy pipeline to Regeneron.
• Chip Baird also expressed excitement about the company's future with the potential to bring Abecma to more patients.

Industry Context

This announcement reflects a trend in the biotech industry where companies are streamlining their focus and divesting assets to concentrate on core programs. The sale to Regeneron allows 2seventy bio to focus on its lead product, Abecma, while Regeneron expands its cell medicines business.

Comparison to Industry Standards

• The divestiture of the oncology and autoimmune pipeline is similar to moves by other biotech companies that have chosen to focus on specific therapeutic areas or products.
• The upfront payment of $5 million is relatively small for a pipeline divestiture, suggesting that the value of the deal is heavily weighted towards the potential milestone payment and royalties.
• The reduction in workforce is a common strategy for companies undergoing strategic realignments, similar to actions taken by other biotech firms facing financial pressures.
• The focus on a single product, Abecma, is a high-risk, high-reward strategy, similar to other companies that have bet heavily on a single lead asset.

Management Changes

Stakeholder Impact

• Shareholders may see a positive impact from the extended cash runway and focus on Abecma, but also face increased risk due to the reliance on a single product.
• Employees have been significantly impacted by the workforce reduction, with approximately 160 employees joining Regeneron.
• Customers (patients) may benefit from the increased focus on Abecma and its potential to reach more patients.
• Suppliers may see a change in demand due to the shift in focus and the sale of assets.
• Creditors may see a reduced risk due to the extended cash runway.

Next Steps

• 2seventy bio will focus on the commercialization and development of Abecma.
• The company will continue to support quality control of lentiviral vector (LVV) for Abecma.
• The company will work to expand capacity and increase manufacturing efficiency for Abecma across the supply chain.
• The company plans to increase the number of Abecma treating sites.

Key Dates

Keywords

2seventy bio, Regeneron, Abecma, asset sale, oncology, autoimmune, CAR T-cell therapy, multiple myeloma, milestone payment, cash runway, strategic realignment